Cargando…

258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C

OBJECTIVES/GOALS: The effect of the Direct-Acting Antiviral (DAA) on hepatic histopathological features from patients treated for HCV has not been thoroughly evaluated. The goals of this retrospective study were to determines differences between the liver biopsies collected before and after DAA trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Millian, Daniel, Saldarriaga, Omar A., Arroyave, Esteban, Wanninger, Timothy, Krishnan, Santhoshi, Rao, Arvind, Moghe, Akshata, Stevenson, Heather L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129449/
http://dx.doi.org/10.1017/cts.2023.321
_version_ 1785030740127252480
author Millian, Daniel
Saldarriaga, Omar A.
Arroyave, Esteban
Wanninger, Timothy
Krishnan, Santhoshi
Rao, Arvind
Moghe, Akshata
Stevenson, Heather L.
author_facet Millian, Daniel
Saldarriaga, Omar A.
Arroyave, Esteban
Wanninger, Timothy
Krishnan, Santhoshi
Rao, Arvind
Moghe, Akshata
Stevenson, Heather L.
author_sort Millian, Daniel
collection PubMed
description OBJECTIVES/GOALS: The effect of the Direct-Acting Antiviral (DAA) on hepatic histopathological features from patients treated for HCV has not been thoroughly evaluated. The goals of this retrospective study were to determines differences between the liver biopsies collected before and after DAA treatment and correlated the histopathology with clinical outcome. METHODS/STUDY POPULATION: Spectral imaging was used to evaluate differences in intrahepatic macrophage (CD68, CD14, CD16, MAC 387, and CD163) and T cell (CD3, CD4, CD8, CD45, and FoxP3) phenotypes in paired liver biopsies collected from the same patient before (n=10) and after (n=10) achieving SVR (Figure 1). Imaging analysis and machine learning algorithms were used to evaluate changes in these key immune cells. We also compared differential gene expression of over 700 genes using RNA isolated from liver biopsies with NanoString. RESULTS/ANTICIPATED RESULTS: Multispectral imaging analysis showed a significant increase of proinflammatory/M1-like (e.g., CD14+) and anti-inflammatory/M2-like macrophage (e.g., CD163+) phenotypes in pre-treatment versus post-treatment biopsies, respectively. Gene expression analysis revealed enrichment of inflammatory (HLA-B, STAT1, CXCL10) and interferon induced-antiviral (ISG15, OAS3, MX1 and IFIT1) genes in the pre-treatment vs the post-treatment group. Cell deconvolution analysis also showed a significant increase of M1-like macrophages in the pre-treatment group when compared to the post-treatment group or controls. Upregulation of genes associated with cell proliferation and differentiation (c-KIT and Fos) was observed in the post-treatment biopsies of patients with persistent inflammatory infiltrates. DISCUSSION/SIGNIFICANCE: Protein and gene expression profiles observed in patients before DAA therapy showed a strong macrophage-mediated inflammatory response against HCV infection in the liver that shifted significantly to a tissue remodeling microenvironment after treatment.
format Online
Article
Text
id pubmed-10129449
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-101294492023-04-26 258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C Millian, Daniel Saldarriaga, Omar A. Arroyave, Esteban Wanninger, Timothy Krishnan, Santhoshi Rao, Arvind Moghe, Akshata Stevenson, Heather L. J Clin Transl Sci Precision Medicine/Health OBJECTIVES/GOALS: The effect of the Direct-Acting Antiviral (DAA) on hepatic histopathological features from patients treated for HCV has not been thoroughly evaluated. The goals of this retrospective study were to determines differences between the liver biopsies collected before and after DAA treatment and correlated the histopathology with clinical outcome. METHODS/STUDY POPULATION: Spectral imaging was used to evaluate differences in intrahepatic macrophage (CD68, CD14, CD16, MAC 387, and CD163) and T cell (CD3, CD4, CD8, CD45, and FoxP3) phenotypes in paired liver biopsies collected from the same patient before (n=10) and after (n=10) achieving SVR (Figure 1). Imaging analysis and machine learning algorithms were used to evaluate changes in these key immune cells. We also compared differential gene expression of over 700 genes using RNA isolated from liver biopsies with NanoString. RESULTS/ANTICIPATED RESULTS: Multispectral imaging analysis showed a significant increase of proinflammatory/M1-like (e.g., CD14+) and anti-inflammatory/M2-like macrophage (e.g., CD163+) phenotypes in pre-treatment versus post-treatment biopsies, respectively. Gene expression analysis revealed enrichment of inflammatory (HLA-B, STAT1, CXCL10) and interferon induced-antiviral (ISG15, OAS3, MX1 and IFIT1) genes in the pre-treatment vs the post-treatment group. Cell deconvolution analysis also showed a significant increase of M1-like macrophages in the pre-treatment group when compared to the post-treatment group or controls. Upregulation of genes associated with cell proliferation and differentiation (c-KIT and Fos) was observed in the post-treatment biopsies of patients with persistent inflammatory infiltrates. DISCUSSION/SIGNIFICANCE: Protein and gene expression profiles observed in patients before DAA therapy showed a strong macrophage-mediated inflammatory response against HCV infection in the liver that shifted significantly to a tissue remodeling microenvironment after treatment. Cambridge University Press 2023-04-24 /pmc/articles/PMC10129449/ http://dx.doi.org/10.1017/cts.2023.321 Text en © The Association for Clinical and Translational Science 2023 https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
spellingShingle Precision Medicine/Health
Millian, Daniel
Saldarriaga, Omar A.
Arroyave, Esteban
Wanninger, Timothy
Krishnan, Santhoshi
Rao, Arvind
Moghe, Akshata
Stevenson, Heather L.
258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
title 258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
title_full 258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
title_fullStr 258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
title_full_unstemmed 258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
title_short 258 Analysis of the Hepatic Microenvironment Before and After Direct-Acting Antiviral (DAA) Therapy for Viral Hepatitis C
title_sort 258 analysis of the hepatic microenvironment before and after direct-acting antiviral (daa) therapy for viral hepatitis c
topic Precision Medicine/Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129449/
http://dx.doi.org/10.1017/cts.2023.321
work_keys_str_mv AT milliandaniel 258analysisofthehepaticmicroenvironmentbeforeandafterdirectactingantiviraldaatherapyforviralhepatitisc
AT saldarriagaomara 258analysisofthehepaticmicroenvironmentbeforeandafterdirectactingantiviraldaatherapyforviralhepatitisc
AT arroyaveesteban 258analysisofthehepaticmicroenvironmentbeforeandafterdirectactingantiviraldaatherapyforviralhepatitisc
AT wanningertimothy 258analysisofthehepaticmicroenvironmentbeforeandafterdirectactingantiviraldaatherapyforviralhepatitisc
AT krishnansanthoshi 258analysisofthehepaticmicroenvironmentbeforeandafterdirectactingantiviraldaatherapyforviralhepatitisc
AT raoarvind 258analysisofthehepaticmicroenvironmentbeforeandafterdirectactingantiviraldaatherapyforviralhepatitisc
AT mogheakshata 258analysisofthehepaticmicroenvironmentbeforeandafterdirectactingantiviraldaatherapyforviralhepatitisc
AT stevensonheatherl 258analysisofthehepaticmicroenvironmentbeforeandafterdirectactingantiviraldaatherapyforviralhepatitisc